The 1.29x P/B sits near the peer cluster, but the forward P/E of 9.63 against a TTM of 10.27 suggests the market expects earnings to soften modestly, consistent with the sequential EPS miss in Q3 2026. With ROE compressing from 3.9% in Q2 2024 to 3.0% in Q3 2026, the multiple appears to reflect a franchise with strong underwriting but a shrinking return on equity, so the discount may be a function of persistency risk rather than a mispricing. Investors should monitor whether ROE stabilizes above 3% before assuming the current multiple is undervalued.

Combined ratios remain far below the 100% underwriting breakeven, so profitability is not in question, but the trajectory from a 21.4% low toward 35% indicates a sustained upward drift in loss and expense absorption. The alternating loss ratios of 5.7% and 28.5% imply that single-quarter combined ratios are unreliable indicators of run-rate performance. Analysts should normalize for reserve development before drawing conclusions about the underlying loss trend.

Because ACT's equity expanded from roughly $4.8B to $5.2B while quarterly net income remained broadly flat, the ROE denominator is absorbing retained earnings faster than the numerator grows. Investment income on float is not separately disclosed in the supplied data, so the relative contribution of underwriting versus portfolio yield cannot be quantified. Investors should treat the low single-digit ROE as a structural feature of an overcapitalized balance sheet rather than a near-term underwriting problem.

The low D/E and high interest coverage indicate that financial leverage poses little constraint, and the relevant underwriting leverage constraint is the PMIERs capital requirement rather than debt. Premium-to-surplus cannot be computed precisely from the supplied data, but the sustained equity base suggests substantial headroom. The more pressing question is whether management can deploy surplus capital productively, since excess capital depresses ROE.

The gap between ACT's ROE and peers is large enough that the P/B premium over RDN and ESNT cannot be explained by return metrics alone, which suggests investors are valuing ACT's persistency-driven book, capital return capacity, or the perceived durability of its insurance in force. The discount to MTG on P/E and the wide ROE gap together imply the market may be applying a complexity or parent-ownership discount. Investors should monitor whether ACT's capital return program narrows the ROE gap over time.